BeiGene is a globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. We believe the next generation of cancer treatment will utilize therapeutics both as monotherapy and in combination to attack multiple underlying mechanisms of cancer cell growth and survival.
Our lead product candidates are BGB-3111 and BGB-A317. BGB-3111 is a potent and highly selective small molecule BTK inhibitor that is currently being evaluated in dose expansion clinical trials as a monotherapy and in combination with other therapies to treat various lymphomas. BGB-A317 is a humanized monoclonal antibody against the immune checkpoint receptor PD-1. It is believed to be differentiated from the currently approved PD-1 antibodies with the ability to bind Fc gamma receptor I specifically engineered out, and has the potential to restore a T-cell’s cancer killing ability by inhibiting PD-1 and removing the blockade of immune activation against cancer.
We also have other clinical stage assets, including BGB-290 and BGB-283. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of PARP1 and PARP2. BGB-290 has the potential to be differentiated from other PARP inhibitors, including olaparib, the only PARP inhibitor currently approved by the FDA and the EMA, in terms of selectivity, DNA-trapping activity, oral bioavailability and brain penetration. BGB-283 is a small molecule RAF kinase inhibitor which is also currently being evaluated in dose expansion clinical trials as a monotherapy and in combination with other therapies to treat cancers with aberrations in the mitogen-activated protein kinase, or MAPK, pathway, including BRAF gene mutations and KRAS/NRAS gene mutations where first generation BRAF inhibitors are not effective.
We have a global team of 215 employees and consultants, including 149 talented scientists and clinicians, with deep scientific knowledge, extensive pharmaceutical experience, and a commitment to improving the lives of cancer patients globally. We have offices and facilities established around the world, including global clinical headquarters in Fort Lee, New Jersey with additional clinical facilities in Australia, New Zealand, and Beijing, China, an R&D center in Beijing, China, a manufacturing plant in Suzhou, China, and operations in Beijing and Shanghai, China, and Boston, Massachusetts.